The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
CARBOPLATIN EPSL (Eugia Pharma (Australia) Pty Ltd)
Product name
CARBOPLATIN EPSL
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
128 (255 working days)
Active ingredients
Carboplatin
Registration type
New generic medicine
Indication
Carboplatin is indicated in the treatment of:
- advanced stage ovarian cancer of epithelial origin
- small cell lung carcinoma
- carcinoma of the head and neck
- carcinoma of the testis
- paediatric cerebral tumours
- soft tissue sarcoma
- neuroblastoma.